Michele Cavo, MD, of Bologna University School of Medicine, Bologna, Italy, discusses the second interim analysis of the EMN02 trial (NCT01208766), which is the largest academic trial so far that aims to compare upfront transplant vs. standard dosing and consolidation vs. no consolidation for multiple myeloma. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.